Respiratory disorders in common variable immunodeficiency  by MARTÍNEZ GARCÍA, M.A. et al.
Respiratory disorders in common variable
immunodeficiency
M. A. MARTI´NEZ GARCI´A*, M. D. HERNA´NDEZ F. DE ROJAS*, M. D. NAUFFAL MANZUR{,
M. P. MUN˜OZ PAMPLONA*, L. COMPTE TORRERO{, V. MACIA´N* AND M. PERPIN˜A´ TORDERA*
Departments of *Pneumology and {Allergology, Hospital Universitario La Fe, Valencia, Spain
Common variable immunodeficiency (CVID) is a heterogeneous immunodeficiency syndrome characterized by
hypogammaglobulinemia, recurrent bacterial infections, and various immunologic abnormalities. The clinical
presentation is generally that of recurrent pyogenic sinopulmonary infections.
Our objectives were to study the prevalence of lung involvement and the response to intravenous
immunoglobulin replacement therapy in 19 patients with CVID. Nineteen patients (12 men) with a mean age
(SD) of 33?1 (17?1) years had a previous diagnosis of CVID and were treated with intravenous immunoglobulin
replacement. All patients underwent complete pulmonary function tests and high-resolution computed tomography
(HRCT) examination. Bronchiectasis was diagnosed in 11 (58%) patients and eight (42%) were multi-lobar
bronchiectasis. Chronic airflow limitation (CAL) was present in 10 (53%) patients and a restrictive pattern was seen
in one case. Eleven patients (58%) presented a decrease in single-breath carbon monoxide diffusing capacity of the
lung (DLCO). Before intravenous immunoglobulin replacement therapy (INIRT), 84% of patients had suffered from
at least one episode of pneumonia. Episodes of lower respiratory tract infection decreased significantly from 0?28
per patient and year before replacement therapy to 0?16 per patient and year after treatment. The mean duration of
replacement therapy was 7?5 years.
In conclusion lung involvement was frequent in patients with CVID. Long-term administration of intravenous
gammaglobulin resulted in a substantial reduction of pneumonic episodes.
Key words: common variable immunodeficiency; bronchiectasis; chronic airflow limitation; pneumonia;
immunoglobulin replacement therapy.
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Common variable immunodeficiency (CVID) is a hetero-
geneous immunodeficiency syndrome characterized by
hypogammaglobulinemia, recurrent bacterial infections of
the upper and lower respiratory tract, and various
immunologic abnormalities. These infections are a direct
result of the deficiency in antibody production — specifi-
cally immunoglobulin G (IgG) — that is the hallmark of
this syndrome (1–6). Amongst populations of European
origin, antibody defects are the most frequent primary
specific immunodeficiency diseases (7–8). The estimated
prevalence of CVID ranges from 1:10 000 to 1:50 000
population (4). Defective antibody formation is accompa-
nied by decreased serum IgG concentrations
(5375mgdl71) (7) and usually by decreased serum IgACorrespondence should be addressed to: Dr Miguel A. Martı´nez
Garcı´a, Department of Pneumology, Hospital Universitario La Fe,
Avda. Campanar 21, E-46009 Valencia, Spain. Fax: +34-96-
3868789; E-mail: med013413@nacom.es
0954-6111/01/030191+05 $35?00/0and IgM concentrations, but other known causes of
humoral immune defects should be excluded (4,5,9).
However, some authors consider the diagnosis of CVID
with serum levels of IgG below 500mgdl71 (1). Although
the number of B-cells may be reduced, the findings in
CVID are consistent with insucient in-vivo stimulus
for B-cell activation rather than an intrinsic failure of B-
cells to differentiate (2). Occasionally, a reduction of CD4þ
T cells can be seen (5). Patients with CVID are susceptible
to recurrent respiratory infections and also have an
increased incidence of autoimmune diseases (pernicious
anaemia, systemic lupus erythematosus, rheumatoid arthri-
tis, Sjo¨gren’s syndrome) and lymphoproliferative disorders
(2–4). Clinically, patients with CVID have recurrent
bacterial infections of the respiratory tract, such as sinusitis,
otitis media, bronchitis and pneumonia (8). Recurrent
pulmonary infections can lead to chronic diseases such as
bronchiectasis and chronic airflow limitation (CAL) (6).
Early intravenous immunoglobulin replacement therapy
(INIRT) has been shown to reduce substantially the
number of sinopulmonary infections (9).
We studied the prevalence of lung involvement and the
response to INIRT in 19 patients with CVID.# 2001 HARCOURT PUBLISHERS LTD
TABLE 1. Respiratory disorders in 19 patients with CVI
Disease No.
patients
%
Recurrent upper respiratory tract infection 19 100
Recurrent pneumonia 14 74
Sinusitis 12 63
Otitis media 12 63
Bronchiectasis 11 58
Chronic obstructive pulmonary disease 9 47
Pulmonary tuberculosis 1 5
Asthma 1 5
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A total of 19 non-consecutive patients (12 men and seven
women) of mean (SD) age 33 (17?1) years (range 12–69
years) who had been diagnosed with CVID and with
ongoing INIRT were included in the study. The sample
included patients with CVID diagnosed at the Departments
of Allergology, Internal Medicine, Paediatrics and Pneu-
mology of our hospital. At diagnosis, all patients showed a
defective antibody formation, serum IgG concentration
5375mgdl71 and other known causes of humoral immune
defects had been excluded. INIRT consisted of intravenous
infusion of IgG, 300–600mgkg71 every 21 days, to
maintain serum IgG concentration 4400mgdl71. All
patients gave informed consent to participate in the study
and the protocol was approved by the Institutional Review
Board.
In all patients, CVID-related clinical manifestations,
particularly respiratory signs and symptoms, were deter-
mined by medical history and physical examination.
Pneumonic event was defined by synchronous occurrence
with acute febrile illness, purulent sputum and new infiltrate
on chest X-ray. Onset of symptoms and date of CVID
diagnosis, dose and duration of INIRT, and adverse
reactions to intravenous immunoglobulin were recorded.
Routine laboratory investigations included complete red
and white blood cell counts with differential lymphocyte
count, serum protein electrophoresis, measurement of
serum immunoglobulins by nephelometry, serum comple-
ment concentrations, and circulating immune complexes.
Blood cultures and sputum smears were also obtained in
patients admitted to the hospital because of pneumonia or
upper respiratory tract infection. All patients had sinus and
chest radiographs and high-resolution computed tomogra-
phy (HRCT) (CT General Electrics Medical System,
Milwaukee, WI, U.S.A.) in order to confirm the presence
of sinusitis and bronchiectasis. Both radiographs and
HRCT were interpreted blindly and independently by a
radiologist and a pulmonologist. A complete pulmonary
function tests including forced spirometry (Collins GS,
MA, U.S.A.) (the best of three manoeuvres was chosen)
with bronchodilator test (with two puffs of salbutamol),
carbon monoxide diffusing capacity (DLCO) measured at
rest using the single-breath carbon monoxide test using
helium dilution method (Collins GS, MA, U.S.A.), and
arterial blood gases (Radiometer ABL 520, Copenhagen,
Denmark) were determined by total and pulmonary
pletysmography (Collins BP, MA, U.S.A.) when required.
Functional values are expressed as percentage of predicted
according to theoretical standards of the European
Respiratory Society.
STATISTICAL ANALYSIS
The Kolmogorov–Smirnov test was used to assess the
normal distribution of variables. Quantitative variables are
expressed as mean and standard desviation (SD), and
categorical variables as percentages. The chi-square (w2)
test (with Fisher’s exact test) was used to compareproportions and the Student’s t-test or the Mann–Whitney
test (or the Wilcoxon’s test for paired data) were used for
the comparison of means. Statistical significance was set at
P50?05.
Results
The mean age at the onset of symptoms was 14?7 years,
with a mean age at diagnosis of CVID of 23?2 years. At the
time of diagnosis, mean serum concentrations of immu-
noglobulins were the following: 160mgdl71 for IgG,
530mg dl71 for IgM, 510mg dl71 for IgA, and
52KU l71 for IgE. No abnormalities were found in white
blood cell counts. Thirteen (68%) of the 19 patients had a
decreased level of B-cells and 15 (79%) patients a low CD4þ
/CD8þ ratio. The absolute number of circulating T cells and
serum complement levels were within normal limits. Circu-
lating immune complexes were detected in three patients.
At the time of inclusion in the study, mean duration of
replacement therapy was 7?5 years. One patient was
withdrawn because of an anaphylactic reaction to INIRT.
As shown in Table 1, respiratory symptoms especially of
the upper respiratory tract were the most frequent clinical
manifestations (100% of patients). Before replacement
therapy, 84% of patients had suffered from at least one
episode of lower respiratory tract infection and 74% had
recurrent episodes of pneumonia. Episodes of lower
respiratory tract infection per patient and year decreased
from 0?28 before INIRT to 0?16 after it (P50?001). The
most common causative pathogens were: Streptococcus
pneumoniae in 37% of cases and Haemophilus influenzae in
26%. Pseudomonas aeruginosa, Staphylococcus aureus and
Corynebacterium spp. were only isolated in patients with
bronchiectasis. However Candida albicans and Cladospor-
ium spp. were isolated in patients without bronchiectasis.
Mycobacterium tuberculosis and Pneumocystis carinii were
isolated in two patients. The prevalence of chronic lung
involvement (bronchiectasis or CAL) was 68?5% in our
patients. Bronchiectasis, the most common radiological
finding, was diagnosed in 11 (58%) cases. Parenchymal
scarring in five patients, pleural thickening in three and
atelectasis in one, were less frequently seen. With regard to
bronchiectasis, the left lower lobe was the most frequently
TABLE 2. Comparison of the groups of patients regarding the presence of bronchiectasis by HR-CT scan
Variable With bronchiectasis
(n = 11)
Without bronchiectasis
(n = 8)
Age (years) 31?6 (19?1) 34?6 (14)
Sex (M/F) 7/4 5/3
Age at diagnosis (years) 21?8 (17?9) 24?6 (19?1)
Age at initiation of symptoms (years) 15?8 (19?7) 13?6 (16?8)
Years on IVIG therapy 8?3 (4?4) 6?7 (4?2)
FEV1 (%) 78?3 (16?5) 100?3 (22?5)*
FEF25–75 (%) 55?1 (25?2) 89?8 (39?3)**
FVC (%) 79?9 (40) 107?8 (12?1)***
TLC (%) 92?2 (9?7) 101?7 (9?6)
RV (%) 112?9 (36?6) 101?8 (28?4)
DLCO (%) 75?9 (13?7) 79?8 (21?5)
PO2 (mmHg) 85?5 (9?2) 89?7 (10?2)
PCO2 (mmHg) 37?5 (3?3) 39?3 (2?6)
IgG (mgdl71) 151 (80) 170 (87)
Leukocytes (per mm3) 10930 (4876) 7817 (2114)
Lymphocytes (per mm3) 2225 (1022) 2157 (789)
B-lymphocytes (CD19þ) 151 (103) 126 (133)
T-lymphocytes (CD3þ) 1704 (1037) 1290 (622)
* P50?03; ** P50?04; *** P50?05.
FEV1: forced expiratory volume in 1 sec; FEF25–75%: force expiratory flow between 25 and 75% of FVC; FVC: forced vital
capacity; TLC: total lung capacity; RV: residual volume; DLCO: diffusing capacity of carbon monoxide.
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lobe (n = 6), right middle lobe (n = 6), and right upper
lobe (n = 1), and were multi-lobar in eight cases and
bilateral in seven patients. Patients with bronchiectasis
showed a moderate impairment of lung function as
compared with patients without bronchiectasis (Table 2).
These two groups of patients showed statistically significant
differences in the mean (SD) values FEV1, 78?3 (16?5) vs.
100?3 (22?5)%; FEF25–75%, 55?1 (25?2) vs. 89?8 (39?3)%;
and FVC 79?9 (39?9) vs. 107?8 (12?1)%. CAL was observed
in 10 patients (53%) it was mild in seven (37%) and
moderate in three (16%) patients, who all had a negative
bronchodilator test, including a patient with asthma. CAL
and bronchiectasis co-existed in eight cases (42%). Eleven
patients presented a decrease of DLCO but a restrictive
pattern was seen in only one case. Gas exchange was
normal in all but one patient.
Discussion
CIVD is a heterogeneous primary immunodeficiency
disease in which B-cells produce little or no antibody. This
rare syndrome affects men and women equally. The
disorder may occur at any age, but in most patients onset
is in the second or third decade of life (4–7). Patients with
CVID have recurrent sinopulmonary infections, such as
sinusitis, otitis media, bronchitis and pneumonia as a direct
result of deficiency in IgG production. It has been reported
that 90% of patients with CVID suffer from one or moreepisodes of acute lower respiratory tract infection through-
out their life, 89% from chronic sinusitis and 70% from
recurrent otitis media (8). In the present series, 84% of
patients had at least one episode of pneumonia, 74%
recurrent episodes of pneumonia and 63% of otitis media
or sinusitis. Encapsulated bacteria are the commonest
pyogenic agents isolated in CVID patients; the most
feasible is that IgG — the major heat-stable opsonin of
extracellular fluid—plays an important role in host defence
against these pathogens.If serum IgG level falls, encapsu-
lated bacteria are likely to be present (5). Pseudomonas
aeruginosa and Staphylococcus aureus account for most of
the respiratory infections in patients with bronchiectasis (6);
Streptococcus pneumoniae and Haemophilus influenzae are
found in those without it (7). The prevalence of infections
by Mycobacterium tuberculosis and Pneumocistis carinii is
low in CIVD, whereas these micro-organisms are usually
present in other immunological disorders (2–4); this is
probably due to the near normal serum CD4þ T cell count
in CIVD which is enough to prevent the development of
these infections which usually occur when CD4þ T cell
levels are very low (2–4). Our findings are similar to those
previously reported, since respiratory infections are usually
caused by S. pneumoniae and H. influenzae, and P.
aeruginosa and S. aureus were only isolated in patients
with bronchiectasis.
The effectiveness of INIRT to reduce the number of
sinopulmonary infections has been extensively documented
(10,11). Our results support these findings since the number
of pneumonic events decreased significantly in the patients
194 M. A. MARTI´NEZ GARCI´A ET AL.of this study after INIRT. The absence of a control group
constitutes a limitation in this study but we considered that
placebo administration in patients with CVID was not
ethical.
It has been found that bronchiectasis were present in
more than half of the patients with CVID (1,12,13). In the
present study bronchiectasis was also the most common
finding and a delay in INIRT existed in most of our
patients. The high prevalence of bronchiectasis in our series
(58%) might be due to several factors, including the low
levels of serum immunoglobulins at diagnosis and the delay
in both diagnosis and INIRT.
Functional respiratory impairment due to development
of bronchiectasis and chronic obstructive pulmonary
disease has been found in CVID patients, and both
obstructive and restrictive patterns have been reported
(1,11,14). CAL can be seen in the early course of the disease
while restriction seems to occur in an advanced stage of
CIVD. More than 50% of our patients had CAL that was
higher in those with widespread bronchiectasis. Thus,
because of the close relationship between these disorders,
our results are in agreement with those of other series
(11,14). It should be noted that, almost 60% of the patients
of the present study presented a decrease of DLCO, which
remains unexplained since none of them had pulmonary
fibrosis or emphysema and only one had a restrictive
pattern (these are conditions where DLCO usually de-
creases). It may be postulated that a decrease in DLCO may
be an early sign of structural damage. With regard to the
changes on pulmonary function tests after INIRT, Watts et
al. (1) demonstrated that FVC and FEV1 remained stable in
adults receiving an adequate INIRT. Although patients
with bronchiectasis showed significantly lower FVC and
FEV1 values when compared with patients without
bronchiectasis, serial pulmonary function tests were not
performed in our study and therefore we can not compare
our results with those of Watts.
Almost 20% of patients with CVID will develop one or
more autoimmune disease, probably because of the co-
existence of a disease causing abnormal immune regulation
and immunodeficiency (6). On the other hand, there is a 30-
fold increase in the incidence of malignant lymphoma
compared with the general population; almost 30% of
patients with CVID will have benign lymphoproliferative
disorders (13,15). We found only one patient with nodular
lymphoid hyperplasia of the mediastinum in whom the
diagnosis was established by mediastinoscopy; pathologi-
cally, nodules consisted of local accumulations of B-
lymphocytes organized into follicles. Other features in
CVID include several types of arthritis, a sarcoid-like
syndrome with disseminated non-caseating granulomata, a
high incidence of herpes zoster, and a 50-fold augmentation
of gastric carcinoma with regard to the general population
(2,6,16). However, none of these conditions were diagnosed
in our patients.
In summary, serum immunoglobulin levels should be
determined in young patients with recurrent sinopulmonary
infections since early recognition of CVID is mandatory.
The prevalence of lung involvement is high, so a HRCT and
pulmonary function test should be carried out in allpatients. Immunoglobulin replacement therapy reduces
pneumonic episodes and should be instituted early in the
course of the disease to prevent repeated sinopulmonary
infections and the development of bronchiectasis.
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